Benson Smith Sells 9,331 Shares of Teleflex Incorporated (TFX) Stock

Teleflex Incorporated (NYSE:TFX) Director Benson Smith sold 9,331 shares of the firm’s stock in a transaction dated Monday, June 25th. The shares were sold at an average price of $275.32, for a total transaction of $2,569,010.92. Following the transaction, the director now directly owns 77,887 shares in the company, valued at $21,443,848.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Benson Smith also recently made the following trade(s):

  • On Monday, June 11th, Benson Smith sold 9,331 shares of Teleflex stock. The shares were sold at an average price of $282.34, for a total transaction of $2,634,514.54.
  • On Monday, May 21st, Benson Smith sold 9,331 shares of Teleflex stock. The shares were sold at an average price of $265.26, for a total transaction of $2,475,141.06.
  • On Monday, May 7th, Benson Smith sold 9,331 shares of Teleflex stock. The shares were sold at an average price of $272.98, for a total transaction of $2,547,176.38.
  • On Monday, April 16th, Benson Smith sold 9,331 shares of Teleflex stock. The stock was sold at an average price of $260.52, for a total transaction of $2,430,912.12.
  • On Monday, April 2nd, Benson Smith sold 9,331 shares of Teleflex stock. The stock was sold at an average price of $251.49, for a total transaction of $2,346,653.19.

Teleflex opened at $269.38 on Friday, according to Marketbeat.com. Teleflex Incorporated has a 12-month low of $197.72 and a 12-month high of $288.78. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.45 and a current ratio of 2.18. The company has a market capitalization of $12.56 billion, a PE ratio of 32.07, a price-to-earnings-growth ratio of 1.94 and a beta of 1.19.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, May 3rd. The medical technology company reported $2.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.21. Teleflex had a net margin of 7.51% and a return on equity of 16.60%. The company had revenue of $587.23 million for the quarter, compared to analyst estimates of $568.29 million. During the same quarter in the previous year, the firm posted $1.80 earnings per share. The company’s quarterly revenue was up 20.4% compared to the same quarter last year. research analysts predict that Teleflex Incorporated will post 9.83 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, June 15th. Stockholders of record on Tuesday, May 15th were given a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 0.50%. The ex-dividend date was Monday, May 14th. Teleflex’s dividend payout ratio (DPR) is currently 16.19%.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Suntrust Banks Inc. bought a new stake in shares of Teleflex in the first quarter valued at approximately $430,000. Summit Trail Advisors LLC raised its position in shares of Teleflex by 12.8% in the first quarter. Summit Trail Advisors LLC now owns 5,623 shares of the medical technology company’s stock valued at $1,181,000 after purchasing an additional 639 shares during the period. WINTON GROUP Ltd bought a new stake in shares of Teleflex in the first quarter valued at approximately $1,378,000. Xact Kapitalforvaltning AB raised its position in shares of Teleflex by 6.9% in the first quarter. Xact Kapitalforvaltning AB now owns 5,683 shares of the medical technology company’s stock valued at $1,449,000 after purchasing an additional 366 shares during the period. Finally, Royal Bank of Canada raised its position in shares of Teleflex by 1.6% in the first quarter. Royal Bank of Canada now owns 33,038 shares of the medical technology company’s stock valued at $8,424,000 after purchasing an additional 527 shares during the period. 89.54% of the stock is currently owned by institutional investors.

Several analysts have commented on TFX shares. ValuEngine lowered shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. TheStreet lowered shares of Teleflex from an “a-” rating to a “c+” rating in a research report on Monday, March 12th. Goldman Sachs Group started coverage on shares of Teleflex in a research report on Wednesday, April 4th. They issued a “neutral” rating and a $257.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $293.00 price objective (up previously from $285.00) on shares of Teleflex in a research report on Thursday, May 3rd. Finally, Deutsche Bank set a $255.00 price objective on shares of Teleflex and gave the stock a “hold” rating in a research report on Friday, May 4th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the stock. Teleflex presently has a consensus rating of “Hold” and a consensus target price of $282.50.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Insider Buying and Selling by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply